What should you conclude when a faecal occult blood test, commonly called an FOBT in Australia, comes back negative?

The accurate answer is reassuring but limited: no blood was detected in the two samples you collected. It does not mean the bowel has been examined, that cancer has been excluded or that new symptoms can wait until the next kit.

That distinction explains why Australia offers the test every two years. The National Bowel Cancer Screening Program uses the immunochemical form of FOBT—often written iFOBT or FIT. It is designed as one round in a repeated screening programme for people who feel well. Its value comes from doing the test when it is due and completing the diagnostic pathway if blood is found.

FOBT looks for blood, not cancer

Australia’s National Bowel Cancer Screening Program is open to eligible people aged 45 to 74. People aged 45 to 49 can request a free kit; from 50 to 74, kits are sent through the established programme. The test is intended for people without signs or symptoms of bowel cancer.

The immunochemical FOBT used in Australia detects human haemoglobin—the oxygen-carrying protein in red blood cells—in faeces using antibodies. The Australian kit asks for samples from two separate bowel motions. A result is reported as positive when at least one sample contains 20 micrograms or more of haemoglobin per gram of faeces.

The test does not see a polyp or tumour. It detects a signal that may come from one. Polyps, haemorrhoids and bowel inflammation can also bleed, which is why a positive result is not a cancer diagnosis. It is a reason to see a doctor and, in most cases, proceed to colonoscopy to find the source.

The reverse is equally important. Some cancers do not bleed continuously. A lesion can be present while both sampled bowel motions contain no detectable blood. The Department of Health says the programme test detects up to 85% of bowel cancers, not all of them. A negative result therefore lowers concern within an asymptomatic screening setting; it does not reduce the probability to zero.

The mortality evidence comes from repeated screening

Long-term randomised evidence shows that stool-based screening can reduce deaths from bowel cancer. A Cochrane review included nine trials, with 338,467 people assigned to screening and 405,919 to control groups. Four trials tested repeated annual or two-yearly faecal occult blood testing. Bowel-cancer mortality was 14% lower than with no screening: risk ratio 0.86, with a 95% confidence interval from 0.80 to 0.92.

Those trials mostly used older guaiac FOBTs, or gFOBTs, which detect blood through a chemical reaction. Australia now uses immunochemical FOBT (iFOBT/FIT), which is specific to human haemoglobin and has different test performance. The older mortality result establishes that organised, repeated stool testing can save lives. It is not an exact forecast of the benefit from one current Australian kit.

Nor does a screening programme end at the laboratory. The benefit depends on people returning kits, receiving results and completing colonoscopy after a positive test. A test left in a drawer has no sensitivity at all.

FOBT and colonoscopy are different strategies

The 2025 COLONPREV trial tested a question that often arises in practice: is invitation to repeated immunochemical FOBT (FIT) merely a second-rate alternative to offering colonoscopy?

Researchers randomised 57,404 presumptively healthy Spanish adults aged 50 to 69 before inviting them to one-time colonoscopy or immunochemical FOBT every two years. People with symptoms, previous bowel cancer or adenomas, inflammatory bowel disease or strong familial risk were excluded. The primary outcome was death from bowel cancer over 10 years.

Participation in some form of screening was 31.8% in the colonoscopy group and 39.9% in the FIT group. In the intention-to-screen analysis, bowel-cancer mortality was 0.22%—55 deaths—in the colonoscopy group and 0.24%—60 deaths—in the FIT group. The absolute difference was 0.02 percentage points, with a confidence interval ranging from 0.10 points in favour of colonoscopy to 0.06 points in favour of FIT. The result met the trial’s prespecified definition of non-inferiority.

This does not make one immunochemical FOBT equivalent to one colonoscopy. Colonoscopy directly examines the bowel lining and can remove a polyp during the procedure. It found more advanced lesions in COLONPREV: 3.2% of the colonoscopy group compared with 2.4% of the FIT group. It also requires bowel preparation and an invasive procedure. Major complications occurred in 0.3% of each assigned group; in the FIT arm, those events followed colonoscopies performed after positive tests.

COLONPREV compared two real screening pathways, including their different participation rates and diagnostic follow-up. It had relatively few bowel-cancer deaths, some people crossed between groups, and its participants were 50 to 69 in Spain. The result cannot decide which test is right for every Australian. It does show why a completed, repeatable FOBT programme should not be dismissed simply because the first step happens at home.

Symptoms change the question

Population screening asks whether an apparently well person has an early signal worth investigating. Symptoms ask why something has changed. Rectal bleeding, persistent altered bowel habit, unexplained iron-deficiency anaemia, abdominal pain, fatigue or weight loss may have many causes, but a recent negative screening kit does not settle them.

Family history can also change the pathway. The routine programme is built for average or slightly above-average risk. A strong family history, previous polyps or bowel cancer, inflammatory bowel disease or an inherited cancer syndrome may call for different testing and intervals.

A useful question for a clinical conversation is: “Am I screening because I feel well, or am I trying to use a screening test to explain a symptom?” If it is screening, returning each two-yearly kit is the intervention tested by the programme. If there is a symptom or higher-risk history, the right next step is an assessment of that problem—not reassurance from two samples collected at an earlier moment.

Sources

Evidence note: This Insight is general education, not individual medical advice or a recommendation for or against a particular test. Bowel symptoms, family history and screening results should be discussed with a qualified clinician.